[CLSTR]
< Back to all clusters
[HEALTH] · Denmark, Norway, Sweden, United States · 7 sources

started · updated

Part of situation: Expanding therapeutic uses and regulatory approvals for GLP- (33 clusters)

Semaglutide and insulin combination shows clinical benefits for type 2 diabetes

semaglutide type 2 diabetes GLP-1 receptor agonists insulin combination therapy cardiovascular risk

New clinical data presented at the European Association for the Study of Diabetes (EASD) congress highlights significant developments in the management of type 2 diabetes using GLP-1 receptor agonists.

Phase 3 Combined studies indicate that a weekly combination of basal insulin and semaglutide is superior to using semaglutide or icodec alone. This regimen shows improved glycemic control, reduces the risk of hypoglycemia, and aids in weight reduction, potentially improving the quality of life for both patients and caregivers.

Regarding safety, an international study involving nearly 100,000 patients from Denmark, Sweden, and Norway found no statistically significant increase in the risk of pancreatic cancer among semaglutide users compared to those on other antidiabetic therapies.

Additionally, real-world COMPETE SWITCH CV data suggests that escalating semaglutide from 1 mg to 2 mg is associated with a 6% lower risk of major adverse cardiovascular events (MACE) compared to switching patients to tirzepatide.

Entities

European Association for the Study of Diabetes · Italian Society of Diabetology · Novo Nordisk · Semaglutide · University of Southern Denmark · semaglutide · tirzepatide

Claims

What the coverage asserts, and how many sources carry each claim.

  • [○ 1 SOURCE] An international study of nearly 100,000 patients found no increased risk of pancreatic cancer associated with semaglutide use. www.ultimenotizieflash.com
  • [● 2 SOURCES] The combination therapy reduces the risk of hypoglycemia. ameve.eu · www.corcianonline.it
  • [○ 1 SOURCE] Escalating semaglutide from 1 mg to 2 mg is associated with a 6% lower risk of major adverse cardiovascular events (MACE) compared to switching to tirzepatide in adults with type 2 diabetes. www.consultantlive.com
  • [● 2 SOURCES] The combination of insulin and semaglutide promotes body weight reduction. ameve.eu · www.corcianonline.it
  • [● 2 SOURCES] Phase 3 Combined studies show that a combination of basal insulin and semaglutide is superior to using semaglutide or icodec alone. ameve.eu · www.corcianonline.it

Sources

Diabete di tipo 2: la terapia combinata riduce i farmaci e il peso [ameve.eu]
Semaglutide e tumore al pancreas, il nuovo studio: nessun aumento del rischio [www.ultimenotizieflash.com]
Diabete, Buzzetti (Sid): "Buoni risultati da combinazione insulina e semaglutide" [www.corcianonline.it]
Was braunes Fett, Stoffwechseltypen und Diätfrust damit zu tun haben • DGP [www.deutschesgesundheitsportal.de]
McDonald’s und Ozempic: Milliardenumbau soll Menü und Filialen verändern [www.ad-hoc-news.de]
Semaglutide 2 mg Escalation Tied to Lower MACE vs Tirzepatide Switch in T2D [www.consultantlive.com]
Patient unter GLP1-RA erbricht plötzlich Kot [www.aend.de]